22
Participants
Start Date
March 20, 2017
Primary Completion Date
May 28, 2020
Study Completion Date
July 17, 2020
daratumumab
Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression or inability to tolerate.
Boston Medical Center, Boston
Lead Sponsor
Collaborators (1)
Janssen Pharmaceuticals
INDUSTRY
Boston Medical Center
OTHER